Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine/Temsirolimus - Freedom Biosciences

Next Previous
Search
Drug Profile

Ketamine/Temsirolimus - Freedom Biosciences

Alternative Names: FREE-001

Latest Information Update: 30 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Freedom Biosciences
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Macrolides; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Biogenic amine uptake modulators; Dopamine receptor agonists; MTOR protein inhibitors; Nicotinic receptor modulators; NMDA receptor antagonists; Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Major depressive disorder

Most Recent Events

  • 25 Apr 2024 US FDA approves IND application for Ketamine/Temsirolimus in Major depressive disorder
  • 25 Apr 2024 Freedom Biosciences plans a phase IIa FREE001-TRD-201 trial for Major depressive disorder (Adjuvant therapy) in the first half of 2024
  • 16 Nov 2022 Early research in Major depressive disorder in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top